ReviewJournal of psychopharmacology (Oxford, England)2024
Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins.
Review in Journal of psychopharmacology (Oxford, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 32 citations in OpenAlex.
- Comparison of acute effects of 3,4-methylenedioxymethamphetamine (MDMA) with and without a supplemental booster dose in healthy participants: a double-blind, randomized, placebo-controlled, crossover study.Translational psychiatry · 2026Trial
- Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. Adults.American journal of preventive medicine · 2026Article
- Psychedelic Safety and Clinical Outcomes Across Exposure Patterns: A Structured Narrative Review.Life (Basel, Switzerland) · 2026Review
- Cardiovascular safety of psilocybin in psychiatric practice: a narrative review.European journal of clinical pharmacology · 2026Review
- U.S. Psychedelic Use and Microdosing in 2025: Insights from a Probability-Based and Nationally Representative Survey.Rand health quarterly · 2026Article
- Association Between Lifetime Hallucinogen Use and Valvular Heart Disease: Findings from the All of Us Research Program.Journal of psychoactive drugs · 2026Article
- TUSI Valve: Echocardiographic and Pathologic Correlates of a Novel Drug-Induced Valvular Disease-a Case Series.CASE (Philadelphia, Pa.) · 2026Article
- The 4-alkyl chain length of 2,5-dimethoxyamphetamines differentially affects in vitro serotonin receptor actions versus in vivo psychedelic-like effects.Molecular psychiatry · 2026Article
- Therapeutic Effects of Low-Dose Psilocybin in Depression and Other Mental Disorders: A Systematic Review.Psychedelic medicine (New Rochelle, N.Y.) · 2026Review
- Predictors of the Effectiveness of Psychedelics in Treating Depression-A Scoping Review.International journal of molecular sciences · 2026Article
- The science of psychedelic medicine.Nature medicine · 2026Review
- Informed Consent in Psychedelic-Assisted Therapy.Current topics in behavioral neurosciences · 2026Review
- Molecules, meaning, and physiology: disentangling the active ingredients of psychedelic therapeutics.Frontiers in neuroscience · 2026Article
- Review
- Microdosing Psychedelics to Restore Synaptic Density in Schizophrenia.International journal of molecular sciences · 2025Review
- Focus on Cognitive Enhancement: A Narrative Overview of Nootropics and "Smart Drug" Use and Misuse.Biology · 2025Review
- Are "mystical experiences" essential for antidepressant actions of ketamine and the classic psychedelics?European archives of psychiatry and clinical neuroscience · 2025Review
- Psychedelic use in individuals living with eating disorders or disordered eating: findings from the international MED-FED survey.Journal of eating disorders · 2025Article
- Lysergic Acid Diethylamide (LSD) and the Heart: Exploring the Potential Impacts of LSD on Cardiovascular Function.Cureus · 2025Review
- Psychedelics and schizophrenia: a double-edged sword.Molecular psychiatry · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Though microdosing psychedelics has become increasingly popular, its long-term effects on cardiac health remain unknown. Microdosing most commonly involves ingesting sub-threshold doses of lysergic acid diethylamide (LSD), psilocybin, or other psychedelic drugs 2-4 times a week for at least several weeks, but potentially months or years. Concerningly, both LSD and psilocybin share structural similarities with medications which raise the risk of cardiac fibrosis and valvulopathy when taken regularly, including methysergide, pergolide, and fenfluramine. 3,4-Methylenedioxymethamphetamine, which is also reportedly used for microdosing, is likewise associated with heart valve damage when taken chronically. In this review, we evaluate the evidence that microdosing LSD, psilocybin, and other psychedelics for several months or more could raise the risk of cardiac fibrosis. We discuss the relationship between drug-induced cardiac fibrosis and the 5-HT2B receptor, and we make recommendations for evaluating the safety of microdosing psychedelics in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.